Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents

Suzanne Nielsen; Pamela Sabioni; Linda Gowing; Bernard Le Foll

doi:10.1007/164_2019_258

Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents

Suzanne Nielsen
, Pamela Sabioni
, Linda Gowing
, Bernard Le Foll

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other

12 Citations (Scopus)

Abstract

This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.

Original language	English
Title of host publication	Substance Use Disorders
Subtitle of host publication	From Etiology to Treatment
Editors	Michael A. Nader, Yasmin L. Hurd
Place of Publication	Cham Switzerland
Publisher	Springer
Pages	355-372
Number of pages	18
Volume	258
ISBN (Electronic)	9783030336790
ISBN (Print)	9783030336783
DOIs	https://doi.org/10.1007/164_2019_258
Publication status	Published - 2020

Publication series

Name	Handbook of Experimental Pharmacology
Volume	258
ISSN (Print)	0171-2004
ISSN (Electronic)	1865-0325

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cannabis
Cannabis dependence
Cannabis use disorder
Pharmacotherapy
Treatment

Access to Document

10.1007/164_2019_258

Cite this

Nielsen, S., Sabioni, P., Gowing, L., & Le Foll, B. (2020). Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. In M. A. Nader, & Y. L. Hurd (Eds.), Substance Use Disorders: From Etiology to Treatment (Vol. 258, pp. 355-372). (Handbook of Experimental Pharmacology; Vol. 258). Springer. https://doi.org/10.1007/164_2019_258

@inbook{7aaa6e46582b4fd086b51de6b2513b9e,

title = "Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents",

abstract = "This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.",

keywords = "Cannabis, Cannabis dependence, Cannabis use disorder, Pharmacotherapy, Treatment",

author = "Suzanne Nielsen and Pamela Sabioni and Linda Gowing and \{Le Foll\}, Bernard",

note = "Applicable ISSNs: 0171-2004 (Print); 1865-0325 (Electronic)",

year = "2020",

doi = "10.1007/164\_2019\_258",

language = "English",

isbn = "9783030336783",

volume = "258",

series = "Handbook of Experimental Pharmacology",

publisher = "Springer",

pages = "355--372",

editor = "Nader, \{Michael A.\} and Hurd, \{Yasmin L.\}",

booktitle = "Substance Use Disorders",

address = "Switzerland",

}

Nielsen, S, Sabioni, P, Gowing, L & Le Foll, B 2020, Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. in MA Nader & YL Hurd (eds), Substance Use Disorders: From Etiology to Treatment. vol. 258, Handbook of Experimental Pharmacology, vol. 258, Springer, Cham Switzerland, pp. 355-372. https://doi.org/10.1007/164_2019_258

Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. / Nielsen, Suzanne; Sabioni, Pamela; Gowing, Linda et al.
Substance Use Disorders: From Etiology to Treatment. ed. / Michael A. Nader; Yasmin L. Hurd. Vol. 258 Cham Switzerland: Springer, 2020. p. 355-372 (Handbook of Experimental Pharmacology; Vol. 258).

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other

TY - CHAP

T1 - Pharmacotherapies for Cannabis Use Disorders

T2 - Clinical Challenges and Promising Therapeutic Agents

AU - Nielsen, Suzanne

AU - Sabioni, Pamela

AU - Gowing, Linda

AU - Le Foll, Bernard

N1 - Applicable ISSNs: 0171-2004 (Print); 1865-0325 (Electronic)

PY - 2020

Y1 - 2020

N2 - This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.

AB - This chapter reviews pharmacotherapies that have been trialled for cannabis dependence, identifying those that warrant further research and those of little or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agonists warrant further research. For the FAAH inhibitor PF-04457845, oxytocin, varenicline and gabapentin, although there is a signal to indicate further research is warranted, these medications do not yet have sufficient evidence to support clinical use, and larger, longer-term trials are needed in representative treatment-seeking populations. Special populations that warrant consideration are those with cannabis dependence and concurrent mental health conditions and those that develop dependence through therapeutic use.

KW - Cannabis

KW - Cannabis dependence

KW - Cannabis use disorder

KW - Pharmacotherapy

KW - Treatment

UR - https://www.scopus.com/pages/publications/85083334353

U2 - 10.1007/164_2019_258

DO - 10.1007/164_2019_258

M3 - Chapter (Book)

C2 - 31375922

AN - SCOPUS:85083334353

SN - 9783030336783

VL - 258

T3 - Handbook of Experimental Pharmacology

SP - 355

EP - 372

BT - Substance Use Disorders

A2 - Nader, Michael A.

A2 - Hurd, Yasmin L.

PB - Springer

CY - Cham Switzerland

ER -

Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents

Abstract

Publication series

UN SDGs

Keywords

Access to Document

Other files and links

Cite this